pCMS-eGFP-RTP801 Citations (3)

Originally described in: RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA J Neurosci. 2006 Sep 27;26(39):9996-10005. PubMed Journal

---

Articles Citing pCMS-eGFP-RTP801

Articles
C/EBPbeta regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Barakat DJ, Mendonca J, Barberi T, Zhang J, Kachhap SK, Paz-Priel I, Friedman AD. Cancer Lett. 2016 May 28;375(1):152-61. doi: 10.1016/j.canlet.2016.03.005. Epub 2016 Mar 8. PubMed
RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Zhang Z, Chu SF, Wang SS, Jiang YN, Gao Y, Yang PF, Ai QD, Chen NH. Br J Pharmacol. 2018 Feb;175(4):590-605. doi: 10.1111/bph.14091. Epub 2018 Jan 17. PubMed
Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Nogami A, Okada K, Ishida S, Akiyama H, Umezawa Y, Miura O. Transl Oncol. 2019 Feb;12(2):336-349. doi: 10.1016/j.tranon.2018.11.001. Epub 2018 Nov 22. PubMed

If you have published an article using this material, please email us at to have your article added to this page.